CRBP
Corbus Pharmaceuticals Holdings, Inc.
$4.05
-1.94%
2026-10-23
About Corbus Pharmaceuticals Holdings, Inc.
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
Key Fundamentals
Forward P/E
-1.30
EPS (TTM)
$-6.11
ROE
-95.6%
Profit Margin
0.0%
Debt/Equity
4.17
Price/Book
1.30
Beta
2.64
Market Cap
$138.1M
Avg Volume (10D)
2.0M
Recent Breakout Signals
Recent Price Range (60 Days)
60D High
$11.60
60D Low
$3.93
Avg Volume
898K
Latest Close
$4.05
Get breakout alerts for CRBP
Sign up for Breakout Scanner to receive daily notifications when CRBP triggers breakout signals. Build custom AI screeners and backtest strategies.
Create your account7-day free trial, no card needed. Then $20/month.
Corbus Pharmaceuticals Holdings, Inc. (CRBP) is listed on the NASDAQ (NASDAQ). Breakout Scanner monitors CRBP daily for breakout patterns including long-term ceiling breakouts, momentum breakouts, and near-breakout watch setups. CRBP operates in the Healthcare sector within the Biotechnology industry. Data is provided for informational purposes only and does not constitute financial advice.